Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01853644 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT01853644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01853644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
June 6, 2013
Completion date
May 11, 2021
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, recurrent primary peritoneal cancer